SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-046516
Filing Date
2023-02-23
Accepted
2023-02-23 16:06:01
Documents
12
Period of Report
2023-02-16
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d433980d8k.htm   iXBRL 8-K 29403
  Complete submission text file 0001193125-23-046516.txt   152897

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA alrn-20230216.xsd EX-101.SCH 2857
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE alrn-20230216_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alrn-20230216_pre.xml EX-101.PRE 11266
6 EXTRACTED XBRL INSTANCE DOCUMENT d433980d8k_htm.xml XML 3446
Mailing Address 285 SUMMER STREET UNIT 101 BOSTON MA 02210
Business Address 285 SUMMER STREET UNIT 101 BOSTON MA 02210 617-995-0900
AILERON THERAPEUTICS INC (Filer) CIK: 0001420565 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38130 | Film No.: 23659600
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences